Clinical Research Directory
Browse clinical research sites, groups, and studies.
Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines
Sponsor: The First Affiliated Hospital of Soochow University
Summary
Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.
Official title: Generation of Tumor-reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2025-07-10
Completion Date
2026-07-10
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
observational study
observational study:Evaluate the broad-spectrum coverage of xenogeneic hybrid lung cancer antigens (including patient tissues and cell lines), and develop a universal whole-cell antigen nanodelivery system to replace autologous tumor-derived preparation
Locations (1)
Soochow university
Suzhou, Jiangsu, China